There is a clinical unmet need to develop a more safe solution to help reduce LDL cholesterol and triglyceride levels without the side effects of current available therapies.
Dyslipidemia is responsible for nearly 20% of the global burden of cerebrovascular disease.
The burden of morbidity, mortality, and the medical costs arising from Dyslipidemia is substantial – Dyslipidemia is responsible for nearly 20% of the global burden of cerebrovascular disease, and 60% of the global burden of ischemic heart disease (IHD), which corresponds to 4.4 million deaths annually (WHO, 2002).
Yet, 30% of the population remains untreated.
As much as 50% of the adult population worldwide suffer from some kind of Dyslipidemia.
Dyslipidemia is a condition in which one or more of the serum lipid (LDL cholesterol and triglycerides) levels are abnormal.
Its prevalence is very common and as much as 50% of the adult population worldwide suffer from some kind of dyslipidemia.
When lifestyle changes are insufficient to reduce lipid levels, statins is the most common treatment to treat high cholesterol levels.
While statins are highly effective, they often cause side effects including:
digestive problems and
They also might cause liver damage.
In addition, statins and other treatment options are usually prescribed only to patients with cholesterol over 190 mg/dL or with existing heart disease or diabetes type 2.
Borderline-high levels of LDL cholesterol:
Many people with borderline-high levels of LDL cholesterol (130-170 mg/dL) and are not in Statins treatment are looking for safer ways ways to decrease their cholesterol level.
Triglyceride-lowering drugs have been available for some time.
The effects of these drugs are somewhat controversial, as several trials showed no benefit from these therapies in preventing heart disease events and caused troublesome side effects, such as flushing of the skin, an increased risk of infections and more.